From a955c126da95e9d8119d40f75961c65877c76abe Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 17:58:51 +0000 Subject: [PATCH] extract: 2026-02-01-glp1-patent-cliff-generics-global-competition Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 12 +++++++++++ ...atent-cliff-generics-global-competition.md | 20 ++++++++++++++++++- 2 files changed, 31 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index bf3d05709..6246cf3e6 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -89,6 +89,18 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. + +### Additional Evidence (challenge) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18* + +International generic competition beginning in 2026 creates price compression trajectory that contradicts the 'inflationary through 2035' timeline. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026 (Biomm + Biocon). China has 17+ generic candidates in Phase 3 with projected pricing of $40-$50/month. India patents expire March 2026. Even with US patents extending to 2031-2032, international price arbitrage and compounding pharmacy pressure will compress US prices faster than the existing claim assumes. If global prices reach $50-100/month by 2030 (5+ years before US patent expiry), the cost-effectiveness calculation flips from inflationary to cost-saving under risk-bearing payment models, especially given the multi-organ protection benefits. + + +### Additional Evidence (extend) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-18* + +Oral Wegovy launched January 2026 at $149-$299/month (Medicare deal: $245/month), representing 75-85% price reduction from injectable formulations. This oral formulation price compression is happening 5-6 years before US generic competition, suggesting the price trajectory may follow a two-phase decline: (1) oral formulation competition 2026-2031, (2) generic competition 2031+. The existing claim's 2035 inflection point may need revision to account for oral formulation price pressure beginning in 2026. + --- Relevant Notes: diff --git a/inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md b/inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md index bbeeccda9..919f37e1e 100644 --- a/inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md +++ b/inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md @@ -7,9 +7,13 @@ date: 2026-02-01 domain: health secondary_domains: [internet-finance] format: article -status: unprocessed +status: enrichment priority: medium tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,17 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure + + +## Key Facts +- Semaglutide US patents extend to 2031-2032 +- Semaglutide Europe patents extend to 2031-2032 +- Canada semaglutide patents expired January 4, 2026 +- Brazil generic semaglutide competition opens March 2026 +- India semaglutide patents expire March 2026 +- China has 17+ generic semaglutide candidates in Phase 3 trials +- Oral Wegovy launched January 2026 at $149-$299/month +- Medicare oral Wegovy deal: $245/month +- Orforglipron (Eli Lilly non-peptide oral GLP-1) potential approval Q2 2026 +- Sandoz, Apotex, Teva filed for Canadian generic semaglutide immediately after patent expiry +- Biomm + Biocon (India) preparing generic semaglutide for Brazil market